Mechanisms and genetics of antipsychotic-associated weight gain

Clinical Pharmacology and Therapeutics

Volumn 90, Issue 1, 2011, Pages 179-183

  Balt, S L ^a   Galloway, G P ^a   Baggott, M J ^a   Schwartz, Z ^a   Mendelson, J ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; AMISULPRIDE; ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; HISTAMINE H1 RECEPTOR; HISTAMINE H2 RECEPTOR ANTAGONIST; ILOPERIDONE; LEPTIN; LURASIDONE; METFORMIN; MUSCARINIC M1 RECEPTOR; MUSCARINIC M3 RECEPTOR; NEUROLEPTIC AGENT; NEUROPEPTIDE Y RECEPTOR; OLANZAPINE; QUETIAPINE; RECEPTOR SUBTYPE; RIMONABANT; RISPERIDONE; SEROTONIN 1A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE; TOPIRAMATE; UNINDEXED DRUG; ZIPRASIDONE;

APPETITE; ARTICLE; BEHAVIOR THERAPY; BODY MASS; BODY WEIGHT; COGNITIVE THERAPY; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIET THERAPY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOCRINE DISEASE; EXTRAPYRAMIDAL SYMPTOM; FOOD INTAKE; GENE MUTATION; HUMAN; HYPERPROLACTINEMIA; HYPOTHALAMUS; MENTAL DISEASE; MOOD DISORDER; NEUROPHARMACOLOGY; NEUROTRANSMISSION; NONHUMAN; OBESITY; PHARMACOGENETICS; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RECEPTOR GENE; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; APPETITE; BIOLOGICAL MARKERS; HUMANS; PHARMACOGENETICS; PROGNOSIS; WEIGHT GAIN;

EID: 79959374794     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.97     Document Type: Article

References (30)

1. Weiden, P.J., Mackell, J.A. & McDonnell, D.D. Obesity as a risk factor for antipsychotic noncompliance. Schizophr. Res. 66, 51-57 (2004). (Pubitemid 38030344)
2. Newcomer, J.W. Antipsychotic medications: metabolic and cardiovascular risk. J. Clin. Psychiatry 68 (suppl. 4), 8-13 (2007). (Pubitemid 46762118)
3. Kahn, R.S. et al.; EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371, 1085-1097 (2008). (Pubitemid 351418005)
4. Farooqi, S. & O'Rahilly, S. Genetics of obesity in humans. Endocr. Rev. 27, 710-718 (2006). (Pubitemid 44936054)
5. Munzberg, H. & Myers, M.G. Jr. Molecular and anatomical determinants of central leptin resistance. Nat. Neurosci. 8, 566-570 (2005). (Pubitemid 40594195)
6. Xu, Y. et al. 5-HT2CRs expressed by pro-opiomelanocortin neurons regulate energy homeostasis. Neuron 60, 582-589 (2008).
7. Tecott, L.H. et al. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 374, 542-546 (1995).
8. Deng, C., Weston-Green, K. & Huang, X.F. The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychoticinduced weight gain? Prog. Neuropsychopharmacol. Biol. Psychiatry 34, 1-4 (2010).
9. Roth, B.L., Sheffler, D.J. & Kroeze, W.K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov. 3, 353-359 (2004). (Pubitemid 38499762)
10. Kroeze, W.K. et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28, 519-526 (2003).
11. Kim, S.F., Huang, A.S., Snowman, A.M., Teuscher, C. & Snyder, S.H. From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc. Natl. Acad. Sci. USA 104, 3456-3459 (2007). (Pubitemid 46364180)
12. Kirk, S.L., Glazebrook, J., Grayson, B., Neill, J.C. & Reynolds, G.P. Olanzapineinduced weight gain in the rat: role of 5-HT2C and histamine H1 receptors. Psychopharmacology (Berl.) 207, 119-125 (2009).
13. Perez-Iglesias, R. et al. Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment. J. Clin. Psychopharmacol. 28, 289-295 (2008).
14. Sentissi, O., Epelbaum, J., Olie, J.P. & Poirier, M.F. Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review. Schizophr. Bull. 34, 1189-1199 (2008).
15. Esen-Danaci, A., Sarandol, A., Taneli, F., Yurtsever, F. & Ozlen, N. Effects of second generation antipsychotics on leptin and ghrelin. Prog. Neuropsychopharmacol. Biol. Psychiatry 32, 1434-1438 (2008).
16. Coccurello, R. & Moles, A. Potential mechanisms of atypical antipsychoticinduced metabolic derangement: clues for understanding obesity and novel drug design. Pharmacol. Ther. 127, 210-251 (2010).
17. Guesdon, B., Denis, R.G. & Richard, D. Additive effects of olanzapine and melanin-concentrating hormone agonism on energy balance. Behav. Brain Res. 207, 14-20 (2010).
18. Minet-Ringuet, J. et al. Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment. Mol. Psychiatry 12, 562-571 (2007). (Pubitemid 46816768)
19. Pavan, C. et al. Weight gain related to treatment with atypical antipsychotics is due to activation of PKC-s. Pharmacogenomics J. 10, 408-417 (2010).
20. Leadbetter, R., Shutty, M., Pavalonis, D., Vieweg, V., Higgins, P. & Downs, M. Clozapine-induced weight gain: prevalence and clinical relevance. Am. J. Psychiatry 149, 68-72 (1992).
21. Henderson, D.C. Weight gain with atypical antipsychotics: evidence and insights. J. Clin. Psychiatry 68 Suppl 12, 18-26 (2007). (Pubitemid 350021619)
22. Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement. Diabetes Care 27, 596-601 (2004).
23. Gebhardt, S. et al. Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course. J. Psychiatr. Res. 43, 620-626 (2009).
24. Baptista, T., Kin, N.M., Beaulieu, S. & de Baptista, E.A. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 35, 205-219 (2002). (Pubitemid 36061310)
25. Baptista, T. et al. Pharmacological management of atypical antipsychoticinduced weight gain. CNS Drugs 22, 477-495 (2008). (Pubitemid 351693690)
26. Muller, D.J. & Kennedy, J.L. Genetics of antipsychotic treatment emergent weight gain in schizophrenia. Pharmacogenomics 7, 863-887 (2006). (Pubitemid 44446736)
27. Reynolds, G.P., Zhang, Z.J. & Zhang, X.B. Association of antipsychotic druginduced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 359, 2086-2087 (2002). (Pubitemid 34680975)
28. Reynolds, G.P. & Kirk, S.L. Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms. Pharmacol. Ther. 125, 169-179 (2010).
29. Templeman, L.A., Reynolds, G.P., Arranz, B. & San, L. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic druginduced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet. Genomics 15, 195-200 (2005). (Pubitemid 40569890)
30. Ruano, G. et al. Physiogenomic comparison of weight profiles of olanzapineand risperidone-treated patients. Mol. Psychiatry 12, 474-482 (2007).